Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) (Tonix) is a clinical-stage biopharmaceutical company committed to discovering and developing innovative and proprietary new therapeutics that address the needs of patients. We focus on developing small molecules and biologics to treat CNS (pain, neurology, psychiatry, addiction) and immunological (vaccines, immunosuppression, oncology, autoimmune disease) conditions.
Our mission is to improve the lives of patients by identifying, researching and developing promising therapies which have the potential to address needs not currently fulfilled by existing products.
Latest News
About Tonix Pharmaceuticals
Tonix’s mission is to advance science to improve patient care and public health. We strive to improve the lives of patients by identifying, researching, and developing promising therapies which have the potential to address needs not currently fulfilled by existing products.
Tonix has a robust pipeline of programs in development stages ranging from preclinical to mid-Phase 3, across a range of therapeutic modalities, employing varied routes of administration. Tonix’s pipeline is managed by a team of passionate professionals that are adept at advancing innovative programs into the clinic.
While many of Tonix’s product candidates are proprietary, in-house developments, it also has collaborations with world-class academic and non-profit research organizations as well as license agreements with other biotech companies.
Therapeutic Areas
Tonix has a robust pipeline of programs in development stages ranging from preclinical to mid-Phase 3, across a range of therapeutic modalities, employing varied routes of administration. Tonix’s pipeline is managed by a team of passionate professionals that are adept at advancing innovative programs into the clinic.
COVID-19 & Biodefense
The ongoing pandemic has shown the world that pandemic preparedness is imminently needed to combat and protect against the likes of viruses like Sars-CoV-2. Tonix’s COVID-19 portfolio targets this viral pandemic from multiple angles – vaccine to prevent, antivirals to cure, T cell diagnostic to detect immunity, therapeutics to manage aftereffects of Long COVID. We are resolute in our goal to provide protection from any future virulent disease.
Central Nervous System
Tonix is dedicated to finding cures for difficult to treat, widely occurring, disorders of the central nervous system. These conditions, pertaining to dysfunctions in the brain and the spinal cord, are chronic and can manifest in multiple ways and their onset could be congenital, genetic, or acquired (through injury, exposure, or infection). At Tonix, we strongly believe in the power of scientific advancements that will help heal sufferings of millions.
Immunology
Our goal with Tonix’s immunology portfolio is to develop therapeutics to improve patient lives. Advancing scientific programs are being expanded to create life-protecting vaccines, therapeutics to prevent organ transplant rejections and compounds that improve responses to immunotherapy in certain cancers.
Therapeutic Areas
Tonix has a robust pipeline of programs in development stages ranging from preclinical to mid-Phase 3, across a range of therapeutic modalities, employing varied routes of administration. Tonix’s pipeline is managed by a team of passionate professionals that are adept at advancing innovative programs into the clinic.
COVID-19 & Biodefense
The ongoing pandemic has shown the world that pandemic preparedness is imminently needed to combat and protect against the likes of viruses like Sars-CoV-2. Tonix’s COVID-19 portfolio targets this viral pandemic from multiple angles – vaccine to prevent, antivirals to cure, T cell diagnostic to detect immunity, therapeutics to manage aftereffects of Long COVID. We are resolute in our goal to provide protection from any future virulent disease.
Central Nervous System
Tonix is dedicated to finding cures for difficult to treat, widely occurring, disorders of the central nervous system. These conditions, pertaining to dysfunctions in the brain and the spinal cord, are chronic and can manifest in multiple ways and their onset could be congenital, genetic, or acquired (through injury, exposure, or infection). At Tonix, we strongly believe in the power of scientific advancements that will help heal sufferings of millions.
Immunology
Our goal with Tonix’s immunology portfolio is to develop therapeutics to improve patient lives. Advancing scientific programs are being expanded to create life-protecting vaccines, therapeutics to prevent organ transplant rejections and compounds that improve responses to immunotherapy in certain cancers.
Pipeline Highlights
Using our integrated clinical development engine, we advance innovative programs into the clinic while maximizing asset potential.
Management Team
“At Tonix, we are developing an innovative, diverse pipeline of therapeutics and diagnostics to address immunological and central nervous system conditions. Our small molecule and biologics product candidates are poised to prevent disease and future public health crises as well as alleviate pain and symptoms of neurologic, psychiatric, and addiction conditions.” — Dr. Seth Lederman, M.D., President and CEO of Tonix Pharmaceuticals.